In the News
-
Seasonal Greetings and Christmas opening hours
19 December 2012
The Gauchers Association would like to take this opportunity of wishing you Seasonal Greetings and very best wishes for 2013. We should also...
Read more....
-
Product Alert for Gaucher Patients and Families
14 December 2012
Dear all, We have been alerted to the existence of another pharmaceutical product called Zavesca that is causing some confusion amongst Gaucher...
Read more....
-
Gaucher Disease scoops Medical Research Grant
13 December 2012
In December 2011, the Medical Research Council (MRC) announced a £60m four-year investment in a Stratified Medicine initiative. Professor Tim...
Read more....
-
Genzyme Gaucher Generation Program Awards 2012
03 December 2012
Genzyme Honors Innovation in Gaucher Disease Research through Its 2012 Gaucher Generation Program Awards Genzyme, a Sanofi com...
Read more....
-
European Commission denies Taliglucerase (Elelyso) market approval for Type 1 Gaucher Disease
07 November 2012
On 3 July 2012, the Committee for Medicinal Products for Human Use (CHMP) recommended the refusal of a marketing authorisation for the medicinal pr...
Read more....
-
The National Collaborative Study for Lysosomal Storage Disorders (NCS-LSD)
06 November 2012
In 2005, the Peninsula Medical School, in collaboration with the Specialist Treatment Centres for Lysosomal Storage Disorders in England, proposed...
Read more....
-
Scottish Medicines Consortium approval of VPRIV
19 October 2012
Shire Human Genetics applied to the Scottish Medicines Consortium (SMC) for approval of VPRIV. The SMC approached The Gauchers Association to provi...
Read more....
-
Patient Advocacy Leadership award from Genzyme
19 October 2012
The Association is pleased to announce they have been successful in achieving a Patient Advocacy Leadership award from Genzyme. This two year proje...
Read more....
-
London Marathon 2013
17 September 2012
The Gauchers Association is pleased to announce a further five Golden Bond places for the 2013 London Marathon. If post London 2012 has inspi...
Read more....
-
Transfer of high cost drugs to NICE risks fragmentation of care of rare diseases
28 August 2012
In an ongoing strategy to raise the profile of the Secretary of State for Health, through the Health and Social Care Act 2012, plans to abolish AGN...
Read more....
-
Future NHS Funding for Gaucher Disease
28 August 2012
The Future of the Advisory Group for national Specialised Services (AGNSS) Future NHS Funding for Gaucher Disease and other Lysosomal Storage D...
Read more....
-
Shire's VPRIV
06 August 2012
At the recent EWGGD meeting in Paris, Shire announced the results of a head to head trial between VPRIV and Cerazyme and the effect that each had o...
Read more....
-
FDA approves new orphan drug to treat a form of Gaucher disease
09 May 2012
The U.S. Food and Drug Administration yesterday approved Elelyso (taliglucerase alfa) for long-term enzyme replacement therapy to treat a form of G...
Read more....
-
Jeremy Manuel "After 21 years"
21 March 2012
I write to let you know that at the most recent Annual General Meeting of the UK Gauchers Association I stood down as its’ Chairman after mor...
Read more....
-
Shire Announces European Approval of Manufacturing Facility for VPRIV
24 February 2012
European Medicines Agency Approval Adds Significant Capacity for the Manufacture of Shire’s Enzyme Replacement Therapies Shi...
Read more....
-
Genzyme Announces FDA Approval of Framingham Manufacturing Plant
08 February 2012
Genzyme, a Sanofi company, announced today that the US Food and Drug Administration (FDA) has approved its manufacturing plant in Framingham, Mass....
Read more....
-
Protalix Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network Symposium
08 February 2012
Protalix BioTherapeutics, announced today that new clinical data on taliglucerase alfa will be presented at the 8th Annual Meeting of the Lysosomal...
Read more....